Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain.

Autor:	Tirado Mercier E; Pharmaceuticals Division Bayer Hispania, SL, Barcelona, Spain., Callejo Velasco D; IQVIA, Madrid, Spain., Rubio Cabezas M; IQVIA, Madrid, Spain., Moretones Agut C; Pharmaceuticals Division Bayer Hispania, SL, Barcelona, Spain., Granell Villalón M; Pharmaceuticals Division Bayer Hispania, SL, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Journal of health economics and outcomes research [J Health Econ Outcomes Res] 2018 Jan 29; Vol. 6 (1), pp. 1-14. Date of Electronic Publication: 2018 Jan 29 (Print Publication: 2018).
DOI:	10.36469/9777
Abstrakt:	Purpose: To perform a cost-effectiveness analysis of radium-223 plus Best Supportive Care (BSC) compared to BSC in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and without previous docetaxel treatment in Spain. Design and Methods: A Markov model was developed to compare radium-223 versus BSC and to accrue the health outcomes and costs of a simulated cohort of mCRPC patients. Quality-adjusted life year (QALY) and life year (LY) were selected as health outcomes to measure the effectiveness of treatment alternatives. Main health resource use and efficacy inputs were obtained from a randomized controlled trial comparing radium-223 versus placebo. Unit costs were retrieved from Spanish databases and published sources. One-way and probabilistic sensitivity analyses were carried out to assess uncertainty. Results: Total costs and QALYs were €65 067 and 1.12 QALYs for radium-223 and €55 437 and 0.77 QALYs for BSC. Therefore, incremental costs per QALY were €27 606. The sensitivity analysis showed that with a willingness-to-pay threshold of €30 000 per QALY, radium-223 would have a probability of 48% of being cost-effective compared to BSC. Conclusions: Although results must be assessed with caution, from the Spanish National Health System perspective and based on the results of the present analysis, radium-223 could be a suitable option of health resources' utilization for end of life mCRPC without previous docetaxel treatment, subject to a moderate level of uncertainty. Competing Interests: Conflict of Interest Declaration CMA, MGV, and ETM are currently employees of Bayer Hispania. MRC and DCV are employees of IQVIA.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu